Search results
Novartis (NVS) Stock Moves -0.4%: What You Should Know
Zacks via Yahoo Finance· 8 months agoNovartis (NVS) closed the latest trading day at $96.10, indicating a -0.4% change from the previous...
Novartis (NVS) Stock Sinks As Market Gains: Here's Why
Zacks via Yahoo Finance· 2 months agoIn the latest trading session, Novartis (NVS) closed at $95.79, marking a -1.14% move from the...
Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
Investor's Business Daily· 2 months agoBiotech stocks heated up Thursday, driven by a spate of deals, as Novartis scooped up a licensing...
Novartis (NVS) Entresto Patent Faces Setback, Stock Down
Zacks via Yahoo Finance· 11 months agoNovartis NVS recently received an unfavorable ruling from the U.S. District Court for the District...
Novartis (NVS) Chronic Myeloid Leukemia Drug Approved by EC
Zacks via Yahoo Finance· 2 years agoNovartis NVS announced that the European Commission (EC) has approved Scemblix (asciminib) for the...
2 Green Flags and 1 Red Flag for Novartis Stock
Motley Fool· 8 months agoShare prices of Swiss pharmaceutical company Novartis (NYSE: NVS) have climbed more than 10% so far this year. The company focuses on cardiovascular,...
Novartis (NVS) Increases Yet Falls Behind Market: What Investors Need to Know
Zacks via Yahoo Finance· 3 months agoNovartis (NVS) closed at $95.88 in the latest trading session, marking a +0.64% move from the prior...
Why Novartis Stock Slipped on Friday
Motley Fool· 11 months agoPharmaceutical companies depend on the patent protection they receive for their goods, so it's never a good day when it is stripped away. The latest...
Exploring Novartis And Two More High-Yield Dividend Stocks In Switzerland
Simply Wall St. via Yahoo Finance· 6 days agoThe Switzerland market recently experienced a moderate decline, influenced by investor concerns that...
Novartis' (NVS) Shareholders Approve Sandoz Separation
Zacks via Yahoo Finance· 9 months agoNovartis AG NVS announced that its shareholders agreed to the proposed 100% spin-off of its generic...